Company Profile
Cel-Sci Corporation Stock Price, News & Catalysts
- Ticker:
- CVM
- Exchange:
- AMEX
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.09 USD (+1.46%)
Close
Last updated: October 1, 2026
21.6M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, CVM closed up 1.46% at $2.09. No new same-company headline was identified in the current news window.
Company overview
Neoadjuvant Cancer Immunotherapy Company
CEL-SCI develops immunotherapies intended to activate the immune system before conventional cancer treatment. Its lead program is directed at newly diagnosed head and neck cancer patients with a defined clinical and biomarker profile.
Multikine Lead Program
Multikine, also known as Leukocyte Interleukin Injection, is a mixture of immune-active proteins administered around the tumor and nearby lymph nodes. Treatment is given before surgery and radiotherapy, when the immune system is less affected by prior cancer therapy.
Head and Neck Cancer Population
The planned confirmatory program focuses on patients with advanced primary squamous cell carcinoma of the head and neck who have no lymph-node involvement and low tumor PD-L1 expression. This subgroup was identified from the company's completed Phase 3 study.
Confirmatory Registration Strategy
The FDA has allowed a confirmatory registration study designed to reproduce the survival benefit observed in the selected population. CEL-SCI must finance and execute this study before Multikine can support a regulatory submission.
LEAPS Research Platform
The company also owns the LEAPS peptide-based immunotherapy platform. Earlier research has explored LEAPS candidates in inflammatory and autoimmune diseases, including rheumatoid arthritis.
Future catalysts
Recent news
- 01
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cel-Sci Corporation (CVM)?
Cel-Sci Corporation (CVM) most recently closed at 2.09 USD, a +1.46% move versus the previous session.
What is the market cap of Cel-Sci Corporation (CVM)?
Cel-Sci Corporation currently has a market capitalization of 21.6M USD on BioPharmSignal.
What does Cel-Sci Corporation do?
Neoadjuvant Cancer Immunotherapy Company CEL-SCI develops immunotherapies intended to activate the immune system before conventional cancer treatment. Its lead program is directed at newly diagnosed head and neck cancer patients with a defined clinical and biomarker profile. Multikine Lead Program Multikine, also known as Leukocyte Interleukin Injection, is...
On which exchange is CVM stock listed?
Cel-Sci Corporation (CVM) is associated with AMEX, United States, Biopharma.
What is CEL-SCI?
Neoadjuvant Cancer Immunotherapy Company CEL-SCI develops immunotherapies intended to activate the immune system before conventional cancer treatment.
Which conditions is Cel-Sci Corporation targeting with CEL-SCI?
Cel-Sci Corporation is associated with cancer therapeutics based on its company overview and current catalyst commentary.
What is PD-L1?
Head and Neck Cancer Population The planned confirmatory program focuses on patients with advanced primary squamous cell carcinoma of the head and neck who have no lymph-node involvement and low tumor PD-L1 expression.
What is Neoadjuvant?
Neoadjuvant Cancer Immunotherapy Company CEL-SCI develops immunotherapies intended to activate the immune system before conventional cancer treatment.